Cannabis Rescheduling 2026: What Schedule III Means for Research, Business, and Federal Law

After more than half a century, cannabis has officially been removed from the federal list of substances grouped with heroin.

On December 18, 2025, President Donald Trump signed a landmark executive order directing the Department of Justice to initiate the process of rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This decision marks the most significant shift in U.S. federal cannabis policy since the CSA was enacted in 1970.

The change means that, at the federal level, cannabis is no longer grouped with substances like heroin and LSD… drugs considered to have “a high potential for abuse and no accepted medical use.”

💡 Key Fact: This Is Not Federal Legalization.
It is important to emphasize that this rescheduling does not mean cannabis is legal at the federal level. Recreational use remains illegal under federal law, and interstate sales are still prohibited. Cannabis remains a controlled substance: just at a lower classification.

Schedule III vs Schedule I: What Changed?

Under the Controlled Substances Act, drugs are classified into five schedules based on their potential for abuse and accepted medical use.

• Schedule I is defined as substances with no accepted medical use and a high potential for abuse. This is the most restrictive category. Heroin, LSD, and MDMA (Ecstasy) are all in this class.

• Schedule III is defined as substances with a moderate to low potential for abuse and accepted medical use. Common Schedule III drugs include ketamine and Tylenol with codeine.

By moving cannabis to Schedule III, the federal government is formally acknowledging its medical value and classifying its abuse risk as significantly lower than that of Schedule I drugs like heroin.

Why Cannabis Was Moved to Schedule III

The rescheduling comes after years of advocacy from researchers, medical professionals, and industry stakeholders. Several factors contributed to this historic shift:

• Growing Medical Evidence: Decades of research have demonstrated cannabis’s therapeutic potential for conditions including chronic pain, nausea, and epilepsy.

• State-Level Legalization: Medical marijuana programs now operate legally in most states, creating a disconnect between federal and state policy.

• Public Opinion: Support for cannabis legalization has reached record highs, with polls showing strong bipartisan backing for reform.

• Scientific Consensus: The Department of Health and Human Services recommended rescheduling in 2023 after a comprehensive review of the evidence.

For consumers interested in exploring high-quality cannabis options, HushHerb offers a curated selection of premium AAA+ flower that meets rigorous quality standards.

What Schedule III Means for Medical Research

For decades, cannabis’s Schedule I status posed a major obstacle to scientific research. Researchers had to navigate burdensome licensing requirements, strict federal oversight, and limited access to products that often did not match what consumers actually use.

Moving cannabis to Schedule III is expected to greatly simplify the process:

• Streamlined Clinical Trials: Researchers will find it easier to conduct clinical trials on specific cannabis formulations.

• Reduced Regulatory Hurdles: DEA oversight and registration requirements will be significantly lowered.

• Expanded Research Scope: Academic medical centers and biopharmaceutical companies can more easily conduct research, leading to clearer insights into how cannabis affects pain, nausea, appetite, memory, mental health, and addiction risk.

As the American Pharmacists Association (APhA) noted, this rescheduling will “accelerate research into its medicinal uses and potentially lead to safer, more effective therapeutic applications.”

Financial Impact: The End of 280E

Beyond research, the rescheduling brings immediate economic benefits to state‑legal cannabis businesses.

The key factor is the removal of Section 280E of the U.S. tax code. This provision prohibits businesses trafficking in Schedule I or II substances from deducting normal business expenses such as rent and payroll.

• Lower Tax Burden: Once cannabis is officially listed as a Schedule III substance, state‑legal cannabis businesses can deduct ordinary business expenses like any other industry, dramatically reducing their effective tax rates.

• Attracting Investment and Banking Services: For years, banks and financial institutions have avoided servicing the cannabis industry due to federal legal risks. This rescheduling is expected to open the door to mainstream banking services and institutional investment.

For those seeking high-quality edible options, HushHerb’s edibles collection offers a variety of premium choices.

What Cannabis Rescheduling Does NOT Change

While the rescheduling is historic, it is essential to understand its limitations:

• ❌ Does Not Legalize Recreational Use: Recreational cannabis remains illegal under federal law.

• ❌ Does Not Allow Interstate Sales: Selling cannabis across state lines is still prohibited.

• ❌ Does Not Overturn State Bans: States can still choose to prohibit cannabis within their borders.

• ❌ Does Not Remove All Restrictions: Cannabis remains a controlled substance with federal oversight.

The DEA Hearing and What Comes Next

Although the executive order has been signed, the formal rescheduling of cannabis still faces legal and procedural challenges.

Administrative Process: Trump’s executive order directed the Attorney General to complete the rulemaking “in the fastest manner possible.” On April 22, 2026, the Department of Justice issued a final order immediately moving FDA‑approved medical cannabis drugs and state‑licensed medical cannabis products to Schedule III. However, recreational cannabis, synthetic THC products, and other items remain in Schedule I.

A full rescheduling of all cannabis products awaits a DEA hearing scheduled for June 29, 2026, and subsequent rulemaking.

Legal Challenges: This historic shift has also drawn legal opposition. Groups such as Smart Approaches to Marijuana (SAM) have filed lawsuits in the D.C. Circuit Court of Appeals challenging the Department of Justice’s order. These legal challenges add uncertainty to the final outcome of the rescheduling process.

Frequently Asked Questions About Cannabis Rescheduling

– Is cannabis federally legal now in 2026?

No. Cannabis has been rescheduled to Schedule III, but it remains a controlled substance. Recreational use is still illegal at the federal level.

– What is the difference between Schedule I and Schedule III?

Schedule I substances have no accepted medical use and a high abuse potential. Schedule III substances have accepted medical use and a moderate to low abuse potential.

– Will cannabis rescheduling affect state laws?

No. States can still prohibit cannabis within their borders. The rescheduling only affects federal classification.

– Can I buy cannabis across state lines now?

No. Interstate cannabis sales remain prohibited under federal law.

– When will the DEA hearing take place?

The DEA hearing on cannabis rescheduling is scheduled for June 29, 2026.

– What does this mean for cannabis research?

Researchers will face fewer regulatory barriers, making it easier to conduct clinical trials and study cannabis’s medical effects.

Looking Ahead: A New Era for Cannabis Policy

Removing cannabis from the same federal category as heroin is a significant step toward aligning U.S. federal policy with science and reality. It acknowledges cannabis’s medical potential and removes key barriers to research and industry growth.

However, as scientists emphasize, rescheduling does not mean cannabis is entirely safe. Rather, it opens the door to more rigorous research that can finally provide clearer answers about where cannabis offers benefits, where it causes harm, and which individuals face the greatest risks.

For the U.S. cannabis industry and research community alike, a new era of opportunity and challenge is just beginning.